Pfizer Shares Jump After FDA Grants 'Fast Track' Status For Coronavirus Vaccine Candidates

Pfizer Inc. shares jumped higher Monday after it received 'fast track' designation by the U.S. Food and Drug Administration for two of its coronavirus vaccine candidates.

a black sign with white letters: Pfizer Shares Jump After FDA Grants 'Fast Track' Status For Coronavirus Vaccine Candidates © TheStreet Pfizer Shares Jump After FDA Grants 'Fast Track' Status For Coronavirus Vaccine Candidates

Pfizer said two candidates from its BNT162 mRNA-based vaccine program, which it its working in collaboration with Germany's BioNTech Inc. , were given the fast track designation based on preliminary data from Phase 1 and Phase 2 studies earlier this month. Early data from the German trial of BNT162b1 are expected to be released in July, Pfizer said.

"The FDA's decision to grant these two COVID-19 vaccine candidates Fast Track designation signifies an important milestone in the efforts to develop a safe and effective vaccine against SARS-CoV-2," said Pfizer's senior vice president of global regulatory affairs Peter Honig. "We look forward to continue working closely with the FDA throughout the clinical development of this program, Project Lightspeed, to evaluate the safety and efficacy of these vaccine candidates."

Pfizer shares were marked 2.84% higher in pre-market trading following the announcement to indicate an opening bell price of $34.79 each, a move that would extend the stock's year-to-date gain to around 12%. BioNTech's U.S.-listed shares rose 8.8% to $76.57 each n the Nasdaq.

Last week, Pfizer said preliminary results of its coronavirus vaccine study that it said triggered a 'strong immune response' in human trials, an unveiled plans to to test the most promising of its four vaccine candidates on up to 30,000 participants in trials set for the United States and Europe.

No serious adverse effects were reported in the study, Pfizer said, which included testing of two BNT1162b1 doses on 24 healthy patient volunteers, but those treated showed higher levels of COVID-19 antibodies when compared to those infected by the disease.

If regulators ultimately approve the drug, Pfizer said, the two companies plan to manufacture up to 100 million doses by the end of the year, and "at least" another 1.2 billion by the end of 2021.


This article was originally published by TheStreet.
Continue Reading
Microsoft may earn an Affiliate Commission if you purchase something through recommended links in this article.

Found the story interesting?

Like us on Facebook to see similar stories

Send MSN Feedback

We appreciate your input!

Please give an overall site rating:

动物老虎机压分技巧 好彩1精准特围技巧 极速11选5微信计划群 甘肃快三推荐预测 炒股票新手入门知识 江西11选5模拟开奖 股票行情今天大盘分析 白小姐精选一码 广西快3第76开奖结果 大发快三大小单双经验 股票涨跌原理举例说明 排三和值走势图带连线 北京pk10最准1期计划 浙江福彩15选5走势图 河北体育彩票11选五结果 上海十一选五分布走势图 辽宁35选七综合走势图